Author Archives: admin


Nick Cordero had stem cell treatment to heal lungs from COVID, wife reveals – Gruntstuff

Coronavirus-stricken Broadway star Nick Cordero has undergone stem cell treatment to assist enhance his lung well being, his wife Amanda Kloots revealed.

We have now began stem cell treatment for Nick and that simply completed. We selected this a few days in the past, Kloots stated in her newest Instagram replace on Corderos well being.

Cordero, 41, has been hospitalized since April at Cedars-Sinai Medical Middle in LA with COVID-19 signs. His leg was amputated due to issues of the virus, and he has struggled with a lingering lung an infection.

Kloots, a 38-year-old health coach, stated Thursday there are no ensures the treatment works, however they hope it can assist restore, assist strengthen Nicks lungs and get him higher. So fingers crossed. Thats the information.

She additionally requested her followers for recommendation on medical therapies that would assist the discharge of carbon dioxide from the lungs.

For those who assume you realize of a health care provider or trial to assist ONLY THAT please attain out to me. Actual medically based mostly data from credited sources please!

See original here:
Nick Cordero had stem cell treatment to heal lungs from COVID, wife reveals - Gruntstuff

Props to You, Californians: A Preview of What’s on Your November Ballot – gvwire.com

This past week marked the deadline for citizens and special interests to snag their spot on the November ballot. (AP File)

After a bit of last-minute legislative maneuvering, the list of propositions that California voters will be asked to weigh in on has been more or less finalized.

Ben Christopher

CalMatters

This past week marked the deadline for citizens and special interests to snag their spot on the Nov.3 ballot. Eight measures made the cut. They address matters as vital and/or esoteric as rent control, property tax law, dialysis clinic staffing requirements, stem cell research funding and the preservation or final dispatch of cash bail in California.

The same date also marked the deadline for legislators to place their preferred measures on the November ballot. But lawmakers have a bit more flexibility when it comes to deadlines.This flexibility gave lawmakers a few extra hours to add four measures: two to expand voting rights, one that ends a 22-year-old ban on affirmative action, and one that is a tortuously complicated property tax measure that somehow ropes in Realtors, wildland firefighters and The Dude from The Big Lebowski.

Heres your November ballot preview:

These three measures, all placed on the ballot by the Legislature, had been introduced before protests against racism and police brutality swept the country. But as California lawmakers look for ways to play a role in the national debate about institutional barriers to equity and the meaning of citizenship, many legislators see these as particularly potent causes.

Ending the ban on affirmative action

Who put it there: The Legislature, via abillby San Diego Democrat Assemblymember Shirley Weber

Type: Constitutional amendment

What it would do: Allow schools and public agencies to take race and other immutable characteristics into account when making admission, hiring or contracting decisions.

In 1996 California voters passedProposition 209, a constitutional amendment banning affirmative action at state institutions. The result was an immediate drop in Black and Latino enrollment at the states elite public universities. Some civil rights organizations have been trying to repeal Prop. 209 ever since.

Each of those attempts has been stymied by a coalition of Republicans, moderate Democrats and some progressive legislators who represent districts with large Asian American voting populations. This year, as in previous years, some of the most vocal and persistent opponents of the effort to reintroduce affirmative action have beenChinese-American political activists. They argue that boosting enrollment of students from underrepresented racial groups would come at the expense of overrepresented Asian American students.

Restoring the right to vote to people on parole

Who put it there: The Legislature, via abillby Sacramento Democrat Assemblymember Kevin McCarty.

Type: Constitutional amendment

What it would do:Allow Californians who are currently on parole to vote.

In 1974, California voters passed a ballot measure giving people who have committed felonies the right to vote once they complete their sentences and are no longer on parole.

Thanks to that law, there are some 40,000 Californians who are not in prison but unable to legally cast a ballot. But as with any criminal justice debate, this is also one about race. According to anestimate from 2016, two thirds of people on parole in the state are Latino or Black.

Letting (some) 17-year-olds vote (some of the time)

Who put it there: The Legislature, with abillintroduced by San Mateo Democrat Assemblymember Kevin Mullin.

Type: Constitutional amendment

What it would do: Allow 17-year-old U.S. citizens to vote in a primary and special election as long as they will turn 18 by the subsequent general election.

California Democrats have been on a decade-long tear increasing voting access. Same-day voter registration, automatic registration at the DMV and pre-registration of 16- and 17-year-olds are among the recent pro-vote innovations to come out of the Capitol.

Letting people under 18 vote would be yet another extension. Already 23 states let 17- year-olds vote in certain circumstances.

Democratic legislators have tried to do this six times before; this is the first to make the ballot.

This wouldnt be a California election without at least a few wildy contentious ballot measures about housing and property taxes.

Split roll

Who put it there: Citizens. Campaign largely funded by the California Teachers Association, SEIU California and the Chan Zuckerberg Foundation

Type: Constitutional amendment

What it would do:Tax some commercial property based on its market value, rather than the price at which it was purchased. This would raise property taxes on many large businesses across the state, increasing funding for schools and local government.

In 1978, California voters passed Proposition 13, placing a cap on property taxes, kicking off a nationwide anti-tax revolt and placing city and county budgets in a generation-spanning straitjacket.

By tying a landlords property tax payments to the original purchase price, Prop. 13 has been thegift that keeps on givingto property owners, particularly those lucky enough to have bought cheap real estate decades ago. Theres been bipartisan reluctance among lawmakers to touch it ever since, lest they incur the wrath of irate homeowners.

This initiative attempts to divide and conquer that political problem by repealing the property tax protections only for commercial landlords with more than $3 million in holdings. If this measure passes, those landowners would have to make tax payments based on the current value of their properties a tax hike for most resulting in anestimated$6.5 to $11.5 billion more for cities, counties and school districts.

Property tax breaks and closing the Lebowski loophole

Who put it there: The Legislature, via abillby San Mateo Democrat Assemblymember Kevin Mullin, but sponsored by the California Realtors.

Type: Constitutional amendment

What it would do: Allow homeowners who are over 55, disabled or victims of natural disaster to take a portion of their property tax base with them when they sell their home and buy a new one. It would also limit the ability of new homeowners who inherit properties to keep their parents or grandparents low property tax payments. Most of the additional money raised would go into a state fire response fund.

Weve seen this one before half of it, anyway. In 2018, the California Association of Realtors put ameasure on the ballotallowing older or disabled homeowners to keep a portion of their Prop. 13 tax break. The Realtors argued that the current property tax rules disincentivize longtime homeowners from moving, trapping empty-nesters in houses that are too big for them and locking out new families. But because the measure would cost schools, counties and cities, it was opposed by organized labor and local government groups and failed by 20 points.

The Realtors tried again this year, but with an added fiscal sweetener. Under this proposal, anyone who inherits a home from their parents or grandparents would only be allowed to keep the low property taxes if they use the home as their primary residence and only on the first $1 million between the homes original purchase price and its market value. Inspiration for that caveat may have come from theLos Angeles Times, which tracked down a number of California scions, including The Big Lebowski star Jeff Bridges, who are still paying 1970-era property tax levels on their rental properties.

And then there was a last-minute wrinkle. In the final weeks of June, the Realtors sprang a deal: designating that most of the funding generated by the measure would go to fighting wildfires. That won the support of the influential California Professional Firefighters union. It also means the measure will be funding a public need that might be on many voters minds come November.

That bargain was struck after the Realtors had submitted their signatures, so with the help of Assemblyman Mullin, they passed it through the Legislature, pulling their original proposal just before the deadline.

Rent Control (Again)

Who put it on the ballot: Signatures, collected via an effort mostly funded by the AIDS Healthcare Foundation.

Type: Statute

What it would do: Allow cities to introduce new rent control laws, or expand existing ones.

Despite a 20-percentage point, 56-out-of-58 county defeat in 2018, a statewide rent control measure is back on the ballot.

Polling from that election seasonsuggestedthat California voters generally liked rent control as a concept, but worried about the specifics of the proposal. Accordingly, this new initiative makes a few tweaks.

Under this one, cities would be allowed to apply new rent control ordinances only to homes that are at least 15 years old. And it exempts single-family homes owned by landlords with no more than two properties.

Just like last time, the measure is being pushed by the Los Angeles-based AIDS Healthcare Foundation and its pugnacious presidentMichael Weinstein. State lawmakers by passing a law last year that set a7% ceilingon how much landlords can raise rents each year had hoped to ward off another attempt by Weinstein and company. They had no such luck.

(Shutterstock)

California, the home of three-strikes sentencing, has spent the last decade rethinking its approach to criminal justice. Two measures on the November ballot, channeling the spirit of the 90s, are pushing to reverse that reversal.

Ditch or keep cash bail

Who put it there: Signatures, via a campaign largely funded by the bail bond industry.

Type: Referendum

What it would do: Ask voters to either approve or strike down a state law that banished money bail from the state criminal justice system.

In 2018, acting on the advice of state Supreme Court Chief Justice Tani Cantil-Sakauye, legislators passed a billending cash bail in California. Rather than letting people pay their way out of jail while they await trial, the law gives judges the right to determine whether someone who is arrested should be kept behind bars based on the risk they are deemed to pose to themselves or others.

Moving quickly, the bail bond industry mounted a campaign to put the question on the ballot as a referendum. Voters will vote either Yes to keep the state law and end cash bail for good, making California the first state to do so, or No to keep the bail system.

Rolling back Brown-era leniency

Who put it there: Signatures, via a campaign largely funded by law enforcement agencies.

Type: Constitutional amendment

What it would do: Allow prosecutors to charge repeat or organized petty theft as a felony, require probation officers to seek tougher penalties for those who violate the term of their parole three times, and exclude those who have been convicted of domestic violence and certain nonviolent crimes from early parole consideration.

Gov. Jerry Brown was famously allergic to talk of his legacy while in office. But if the former governor has one, it might be the effort he spent in his final two terms as governor supporting efforts to reverse the tough on crime policies he helped introduce during his first two terms in the 1970s and 80s.

In 2011, California legislators reduced punishments for parole violators. In 2014, voters passed Proposition 47, recategorizing some non-violent crimes as misdemeanors. In 2016, voters passed Proposition 57, giving inmates convicted of certain non-violent offenses a shot at early release.

This ballot measure would partially undo each of those.

Usually standoffs between employees and their bosses take place behind closed doors. In California, you often find them on the ballot.

Self-employment for ride-hail and other app-drivers

Who put it there: Signatures, via a campaign mostly funded by Lyft, Uber and Doordash

Type: Statute

What it would do: Turn app-based drivers into independent contractors, exempting companies such as Lyft and Uber from standard wage and hour restrictions. It would also guarantee these drivers an earnings floor, a stipend to purchase health insurance and other minimum benefits.

Unless you happen to be ananti-vaccine protestor, the most controversial law of the 2019 legislative session wasAssembly Bill 5. On its face, the law simply codified a state Supreme Court ruling, making it much harder for companies to treat their workers as independent contractors, rather than full-fledged employees. In practice, it upended the business models of Uber, Lyft, Doordash, Postmates and Instacart, all of which rely on an army of phone-toting gig-workers to provide their various services.

In the months since, all attempts at legislative compromise have fizzled, Californias Attorney General hassued Uber and Lyftfor violating the new law and California regulatorsdeclaredtheir drivers to be employees.

As a last-ditch effort, the various companies implicated have poured $110 million and counting to push a ballot measure that would simply exclude their drivers from the law. And throwing a bone to critics who say their drivers are mistreated, the measure also imposes some worker benefits and protections.

Regulating dialysis clinics

Who put it there: Signatures, via an effort funded entirely by the Service Employees International Union-United Healthcare Workers West

Type: Statute

What it would do: Require dialysis clinics to have at least one physician on site at all times and to report patient infection data to California health officials.

DaVita Kidney Care and Fresenius Medical Care own the majority of the for-profit dialysis clinics in the state. For years, the Service Employees International Union-United Healthcare Workers union has been at war with them.

After unsuccessful efforts to unionize clinic staff, the union sponsored legislation to cap reimbursement rates to clinics and floated an array of possible ballot measures to boost their staff spending and cut their profits. In 2018, the union finally got one on the ballot:Prop 8, which would have set a cap on clinic profit margins.

The measure was soundly defeated, but only after the two companies spent over $111 million, making it the most expensive ballot campaign ever. This one isnt likely to be much cheaper.

FILE In this Jan. 12, 2016, file photo, a ride share car displays Lyft and Uber stickers on its front windshield in downtown Los Angeles. Law enforcement agencies and ride-hailing companies are intensifying efforts to warn passengers against getting in without checking to ensure both the vehicle and driver are legitimate. (AP Photo/Richard Vogel, File)

Two measures on this years ballot aim to bolster laws and programs already on the books. Both campaigns are led by Bay Area real estate developers with a penchant for ballot box policymaking.

Stronger consumer privacy laws (again)

Who put it there: Signatures, via a campaign funded entirely by Alastair and Celine Mactaggart.

Type: Statute

What it would do: Strengthen Californias already strongest-in-the-nation consumer privacy law and establish a California Privacy Protection Agency

In 2018, California lawmakers passed theCalifornia Consumer Privacy Act, giving consumers the right to find out what data companies are collecting about them, to opt out of having it collected and to have that data scrubbed. It was and remains the only law like it in the county. It was also acompromise. San Francisco real estate developer Alastair MacTaggart had been pushing for an even stricter ballot measure, but the Legislature stepped in, brokering a deal between MacTaggart and the tech industry.

Now MacTaggart is back. Along with setting up a state agency tasked with enforcing state privacy law, the measure would beef up financial penalties for violators and allow consumers to demand that personal information not be shared at all, rather than simply not sold.

Borrowing for stem cell research

Who put it there: Signatures via an effort mostly funded by Robert Klein, JDRF International and Open Philanthropy

Type: Bond

What it would do: Borrow $5.5 billion to fund stem cell research

In 2004, voters passed Proposition 71 to create the California Institute for Regenerative Medicine. The institute exists to channel state money toward stem cell research. Prop 71 also let the state borrow $3 billion to do that.

That pot of cash is now almost empty. Robert Klein, a Silicon Valley real estate developer who led the Prop. 71 effort and became the institutes first board chair, is leading the campaign for more.

2020 ElectionCalifornia votersGov. Gavin Newsom

Originally posted here:
Props to You, Californians: A Preview of What's on Your November Ballot - gvwire.com

Goal of Plentiful Organ Transplants Moves Closer to Reality as Scientists Grow Tiny Working Livers from Skin Cells – Good News Network

As reported in an eye-opening new research paper, scientists have created tiny human livers out of human skin cells before successfully transplanting them into rats.

What we are planning to do is to start making mini human organs that are universal, explained the papers co-author, Alejandro Soto-Gutirrez, from the University of Pittsburgh.That would change the paradigm of transplants.

The science-fiction-like procedure was done by taking adult skin cells and genetically altering certain genes and transcription factors to create what are known as pluripotent stem cells.

It starts with human skin cells called fibroblasts, in 2006 the pioneering field of genetic-editing led scientists to discover that they can simply take any cell from a living adult and turn it into a pluripotent stem cell.

Pluri, meaning plurality, indicates its ability to carry the genetic code of all organ types, which is how they can become liver cells.

RELATED: For the First Time in the US, Surgeons Pump New Life into Dead Donor Heart for Life-Saving Transplant

According to the Mayo Clinic, the number of people on current waiting lists for liver transplants far exceeds the number of available liver donors. The cost is just as high: the medical journal Inverse reports the average cost of a transplant, accounting for the entire procedure, is about $812,000.

New technologies always reduce the cost of existing products (remember how expensive flat screen televisions were?) and a new paradigm of made-to-order fabrication of organs would likely fulfill all the demand for transplants while lowering the cost at the same time.

As fascinating as it is a little unsettling, the science took a decade to perfect, but is far still from human trials. The tiny organs from human cells continued working normally after they were transplanted into rats bred to have suppressed immune systems otherwise the body would reject the foreign organ.

RELATED: Game-Changing Approval of Liver Transplant Procedure Expected to Halve the Waiting List

The method and associated technology could produce part-time liver grafts, that could prolong the lives of people waiting on the transplant list.

The long-term goal is to create organs that can replace organ donation, but in the near future, I see this as a bridge to transplant, Soto-Gutirrez told Inverse. For instance, in acute liver failure, you might just need a hepatic boost for a while, instead of a whole new liver.

(File photo by OPCW Laboratory in Rijswijk, CC license)

YOUR Friends May Be On The Waiting List For Good NewsShare on Social Media

Visit link:
Goal of Plentiful Organ Transplants Moves Closer to Reality as Scientists Grow Tiny Working Livers from Skin Cells - Good News Network

Tony Delk IMAC Regeneration Center helps heal bodies without surgery or opioids – The Sentinel-Echo

With their two-year anniversary approaching, The Tony Delk IMAC Regeneration Center in Lexington continues to help heal bodies without surgery or opioids.

The center, which specializes in sports injuries, back and neck pain, arthritis and joint pain, is currently accepting new patients with no referral needed.

Delk is a member of the University of Kentucky mens basketball team that won the 1996 NCAA Championship. He went on to play professionally and is now a brand ambassador for the center.

The center is philosophically driven to treat patients for movement disorders without surgery or opioids. Those disorders may include osteoarthritis, disc herniation, soft tissue sprains and sports injuries. The centers medical director, Dr. Donald Douglas, has a background in anesthesiology and pain management.

Douglas is a graduate of the University of Kentucky and continues to stay active with them. He also has a nurse practitioner who works alongside him.

With a full physical therapy department, the center is able to collaboratively work with physical therapy as well as the medical director during treatment. Chiropractic services are also available.

We can handle from the most conservative way to treat somebody all the way up to invasive injections and interventional pain management techniques, said Joe Verna, a spokesperson for the company.

The center focuses both on traditional injections and cellular therapy, where they take the body's own cells and use them to regrow cartilage or reduce inflammation in the joint. Platelet rich plasma and cellular therapy treatments use a patient's own blood and cells to heal their body from the inside out.

The biggest thing we see are spinal related issues, said Verna. We also see a lot of osteoarthritis of the knees and hips.

Verna added that obviously with Delk as an ambassador, the center sees a lot of sports injuries where they can use cellular therapy. Delk has experienced first hand what the center is capable of.

It helped him in his career and thats what made him a believer in what we do, Verna added.

Delk is active with the center, coming by often and interacting with patients, and of course he signs autographs.

We have a lot of NCAA college athletes coming to us, said Verna. We have the professional or high level athletes who are looking for recovery. IMAC is also expanding into helping high school athletes heal quickly.

However the number one patient base is arthritic patients 60 years of age and over with basic wear and tear.

Verna recalls a high level professional football player who was on the bottom end of the roster trying to make the team when he got hurt during summer camp.

He was worried he was going to lose his spot, Verna said. He came to our office for cellular therapy and very quickly healed. We were able to get him back to training camp.

This player not only made the team but by the end of the year he became a starter.

To be able to see that and work with that was a phenomenal thing, added Verna Thats one of the success stories that I always stick with.

Equally important are the elderly patients who throw their back out and fear theyll never walk again, and thanks to the IMAC Regeneration Centers, they are up and walking again in no time.

According to Verna, the IMAC Regeneration Centers are often the last line of defense before surgery.

For more information or to schedule a visit, go to http://www.tonydelkcenter.com.

See the original post here:
Tony Delk IMAC Regeneration Center helps heal bodies without surgery or opioids - The Sentinel-Echo

Biopreservation Market 2020 Global Analysis, Size, Growth, Covid-19 Impact Analysis, Leading Players, Merger, Acquisition, Opportunity, With Regional…

Biopreservation Market Overview

Biopreservation is the preservation of biological materials through the use of natural flora and its antibacterial products and forms an integral part in both the food and healthcare industry. The global biopreservation market is on an upward growth trajectory and is estimated to strike a CAGR of 11.2% over the forecast period of 2018-2023, predicts Market Research Future (MRFR).

Adult mesenchymal stem cells have gained huge momentum as it is a promising source for cell therapies and tissue engineering applications due to which the demand for stem cell preservation has increased drastically. Biopreservation is a crucial aspect of cell and gene-based therapy biopreservation. Growth in number of cryogenic storage facilities is expected to induce high demand within the global biopreservation market.

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @https://www.marketresearchfuture.com/sample_request/6407

Biopreservation has substantial significance in the food industry. Biopreservation is extensively used in the preservation of various food products such as dairy and meat products since they can cause great economic loses. Surging awareness regarding the risks associated with the transmission of foodborne pathogens has evoked greater interest in the application of biopreservation techniques in food safety and food preservation. Moreover, biopreservation is the only viable technique which can be applied to certain food products where other techniques can be used. Furthermore, microbiological safety standards and rise in the incidence of food spoilage, and growing consumption of precooked foods are other factors which generate massive demand for biopreservation from the food industry.

The global biopreservation market is also growing in tandem with recent advances in interrelated, emerging and evolving field of biospecimen procurement, processing, preservation and banking, distribution, and use.

On the downside, biopreservation instruments and their maintenance is a cost-intensive which is a major impediment to the market growth. Moreover, stability issues surrounding specimen and dearth of trained professionals to perform and handle the biopreservation process are other possible bottlenecks to the growth of the global biopreservation market.

Biopreservation MarketSegmentation

The global biopreservation market has been segmented based on product, biospecimen, and application.

By product, the global biopreservation market has been segmented into media and equipment. The media segment has been further segmented into nutrient media, sera, and growth factors and supplements.

The equipment segment has been further segmented into temperature control systems, accessories, alarms & monitoring systems, incubators, centrifuges, and other equipment. The temperature control systems sub-segment has been further segmented into freezers, cryogenic storage systems, thawing equipment, and refrigerators.

By biospecimen, the global biopreservation market has been segmented into human tissue samples, organs, stem cells, and other biospecimens.

By application, the global biopreservation market has been segmented into regenerative medicine, biobanking, and drug discovery. The regenerative medicine segment has been further segmented into cell therapy, gene therapy, and others.

The biobanking segment has been further segmented into human eggs, veterinary IVF, and human sperm.

Biopreservation MarketRegional Analysis

By region, the global biopreservation market has been segmented into the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).

The Americas account for the largest share of the globalbiopreservation market. Extensive utilization of advanced technologies, high expenditure on R&D activities, and the existence of key players in the region are favoring the growth of the global biopreservation market in the Americas region. Moreover, merger and acquisition have been adopted as key strategies by market players which further contributes to the growth of the market.

Europe is the second largest market within the global biopreservation market. Prevalent trend of stem cell preservation coupled with high birth rate in the region substantiates the growth of the market. The rise in a number of sperm and egg banks in the region is also contributing positively to the market growth.

APAC biopreservation market is estimated to expand at a relatively faster rate than other markets. Booming population, the surge in the awareness level of stem cell preservation and persistent development within the healthcare sector are factors triggering growth within the APAC market.

MEA market accounts for the least share of the global market owing to the underdeveloped healthcare sector in the region, lack of technical know-how and poor medical facilities.

Biopreservation MarketCompetitive Landscape

Thermo Fisher Scientific, Inc., Core Dynamics, Ltd., ATLANTA BIOLOGICALS, VWR International, LLC., BioLifeSolutions Inc., Princeton CryoTech, Lifeline Scientific, QIAGEN, Cesca Therapeutics Inc., Panasonic Biomedical, Inc., Chart Industries, Sigma-Aldrich Co., CUSTOM BIOGENIC SYSTEMS., BioCision., and Biomatrica, Inc. are the key players in the global biopreservation market.

Biopreservation Industry Updates

March 2019- BioLife Solutions, Inc., a leading manufacturer, marketer, and developer of proprietary cell and tissue hypothermic storage and cryopreservation freeze media, announced the acquisition of Astero Bio, a company focused on innovation, design, development, and commercialization of novel automated thawing devices. The transaction was closed for an amount of USD 8 Mn.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @https://www.marketresearchfuture.com/reports/biopreservation-market-6407

About Market Research Future:

AtMarket Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email:[emailprotected]

NOTE: Our team of researchers are studying Covid-19 and its impact on various industry verticals and wherever required we will be considering covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

See original here:
Biopreservation Market 2020 Global Analysis, Size, Growth, Covid-19 Impact Analysis, Leading Players, Merger, Acquisition, Opportunity, With Regional...

Stem Cell-Derived Cells Market is Projected to Reach US$XX by the end of 2019 2029 – 3rd Watch News

Global Stem Cell-Derived Cells market Research presents a Comprehensive scenario Which can be segmented according to producers, product type, applications, and areas. This segmentation will provide deep-dive analysis of the Stem Cell-Derived Cells business for identifying the growth opportunities, development tendencies and factors limiting the development of the marketplace. This report features forecast market information based on previous and present Stem Cell-Derived Cells industry scenarios and growth facets. Each of the Essential regions coated in Stem Cell-Derived Cells report are North America, Europe, Asia-Pacific, South America, Middle East and Africa. The Stem Cell-Derived Cells market share and market prognosis of every region from 2020-2027 are presented within this report. A deep study of Stem Cell-Derived Cells marketplace dynamics will help the market aspirants in identifying the business opportunities that will lead to accumulation of earnings. This segment can efficiently determine the Stem Cell-Derived Cells hazard and key market driving forces.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/28780

The Stem Cell-Derived Cells report is segmented to provide a clear and Precise view of this international Stem Cell-Derived Cells market statistics and market quotes. Stem Cell-Derived Cells report Information represented in the form of graphs, charts, and statistics will show the Stem Cell-Derived Cells growth rate, volume, goal customer analysis. This report presents the significant data to all Stem Cell-Derived Cells business aspirants which will facilitate useful business decisions.

key players in stem cell-derived cells market are focused on generating high-end quality cardiomyocytes as well as hepatocytes that enables end use facilities to easily obtain ready-made iPSC-derived cells. As the stem cell-derived cells market registers a robust growth due to rapid adoption in stem cellderived cells therapy products, there is a relative need for regulatory guidelines that need to be maintained to assist designing of scientifically comprehensive preclinical studies. The stem cell-derived cells obtained from human induced pluripotent stem cells (iPS) are initially dissociated into a single-cell suspension and later frozen in vials. The commercially available stem cell-derived cell kits contain a vial of stem cell-derived cells, a bottle of thawing base and culture base.

The increasing approval for new stem cell-derived cells by the FDA across the globe is projected to propel stem cell-derived cells market revenue growth over the forecast years. With low entry barriers, a rise in number of companies has been registered that specializes in offering high end quality human tissue for research purpose to obtain human induced pluripotent stem cells (iPS) derived cells. The increase in product commercialization activities for stem cell-derived cells by leading manufacturers such as Takara Bio Inc. With the increasing rise in development of stem cell based therapies, the number of stem cell-derived cells under development or due for FDA approval is anticipated to increase, thereby estimating to be the most prominent factor driving the growth of stem cell-derived cells market. However, high costs associated with the development of stem cell-derived cells using complete culture systems is restraining the revenue growth in stem cell-derived cells market.

The global Stem cell-derived cells market is segmented on basis of product type, material type, application type, end user and geographic region:

Segmentation by Product Type

Segmentation by End User

The stem cell-derived cells market is categorized based on product type and end user. Based on product type, the stem cell-derived cells are classified into two major types stem cell-derived cell kits and accessories. Among these stem cell-derived cell kits, stem cell-derived hepatocytes kits are the most preferred stem cell-derived cells product type. On the basis of product type, stem cell-derived cardiomyocytes kits segment is projected to expand its growth at a significant CAGR over the forecast years on the account of more demand from the end use segments. However, the stem cell-derived definitive endoderm cell kits segment is projected to remain the second most lucrative revenue share segment in stem cell-derived cells market. Biotechnology and pharmaceutical companies followed by research and academic institutions is expected to register substantial revenue growth rate during the forecast period.

North America and Europe cumulatively are projected to remain most lucrative regions and register significant market revenue share in global stem cell-derived cells market due to the increased patient pool in the regions with increasing adoption for stem cell based therapies. The launch of new stem cell-derived cells kits and accessories on FDA approval for the U.S. market allows North America to capture significant revenue share in stem cell-derived cells market. Asian countries due to strong funding in research and development are entirely focused on production of stem cell-derived cells thereby aiding South Asian and East Asian countries to grow at a robust CAGR over the forecast period.

Some of the major key manufacturers involved in global stem cell-derived cells market are Takara Bio Inc., Viacyte, Inc. and others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/28780

The Stem Cell-Derived Cells report cover following data points:

Part 1: This part enlists the global Stem Cell-Derived Cells marketplace Overview, covering the simple market debut, market analysis by kind, applications, and areas. Stem Cell-Derived Cells industry states and prognosis (2020-2027) is presented in this part. Additionally, Stem Cell-Derived Cells market dynamics saying the chances, market risk, and key driving forces are studied.

Part 2: This part covers Stem Cell-Derived Cells manufacturers profile based On their small business overview, product type, and application. Additionally, the sales volume, Stem Cell-Derived Cells product price, gross margin analysis, and Stem Cell-Derived Cells market share of every player is profiled in this report.

Part 3 and Part 4: This part presents the Stem Cell-Derived Cells competition Based on earnings, earnings, and market share of each producer. Part 4 covers the Stem Cell-Derived Cells market scenario based on regions. Region-wise Stem Cell-Derived Cells sales and growth (2015-2019) is studied in this report.

America and Europes Stem Cell-Derived Cells industry by countries. Under this Stem Cell-Derived Cells revenue, market share of those nations like USA, Canada, and Mexico is provided. Under Europe Stem Cell-Derived Cells report contains, the countries such as Germany, UK, France, Russia, Italy, Russia and their sales and growth is coated.

Part 7, Part 8 and Part 9: These 3 sections covers Stem Cell-Derived Cells The earnings and expansion in these regions are presented in this Stem Cell-Derived Cells industry report.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/28780

Part 10 and Part 11: This component depicts the Stem Cell-Derived Cells marketplace Share, earnings, sales by product type and application. The Stem Cell-Derived Cells sales growth seen during 2012-2020 is covered in this report.

Related to Stem Cell-Derived Cells market (2020-2027) for every region. The sales channels including indirect and direct Stem Cell-Derived Cells advertising, traders, distributors, and future trends are presented in this report.

Part 14 and Part 15: These components present Stem Cell-Derived Cells market key Research findings and judgment, research methodology, and data sources are covered.

Therefore, Global Stem Cell-Derived Cells report is a complete blend covering all The very important market aspects.

Continued here:
Stem Cell-Derived Cells Market is Projected to Reach US$XX by the end of 2019 2029 - 3rd Watch News

Takeda and the New York Academy of Sciences Announce 2020 Innovators in Science Award Winners – Business Wire

NEW YORK & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (Takeda) (TSE:4502/NYSE:TAK) and the New York Academy of Sciences announced today the Winners of the third annual Innovators in Science Award for their excellence in and commitment to innovative science that has significantly advanced the field of rare disease research. Each Winner receives a prize of US $200,000.

The 2020 Winner of the Senior Scientist Award is Adrian R. Krainer, Ph.D., St. Giles Foundation Professor at Cold Spring Harbor Laboratory. Prof. Krainer is recognized for his outstanding research on the mechanisms and control of RNA splicing, a step in the normal process by which genetic information in DNA is converted into proteins. Prof. Krainer studies splicing defects in patients with spinal muscular atrophy (SMA), a devastating, inherited pediatric neuromuscular disorder caused by loss of motor neurons, resulting in progressive muscle atrophy and eventually, death. Prof. Krainers work culminated notably in the development of the first drug to be approved by global regulatory bodies that can delay and even prevent the onset of an inherited neurodegenerative disorder.

Collectively, rare diseases affect millions of families worldwide, who urgently need and deserve our help. Im extremely honored to receive this recognition for research that my lab and our collaborators carried out to develop the first approved medicine for SMA, said Prof. Krainer. As basic researchers, we are driven by curiosity and get to experience the thrill of discovery; but when the fruits of our research can actually improve patients lives, everything else pales in comparison.

The 2020 Winner of the Early-Career Scientist Award is Jeong Ho Lee, M.D., Ph.D, Associate Professor, Korea Advanced Institute of Science and Technology (KAIST). Prof. Lee is recognized for his research investigating genetic mutations in stem cells in the brain that result in rare developmental brain disorders. He was the first to identify the causes of intractable epilepsies and has identified the genes responsible for several developmental brain disorders, including focal cortical dysplasias, Joubert syndromea disorder characterized by an underdevelopment of the brainstemand hemimegalencephaly, which is the abnormal enlargement of one side of the brain. Prof. Lee also is the Director of the National Creative Research Initiative Center for Brain Somatic Mutations, and Co-founder and Chief Technology Officer of SoVarGen, a biopharmaceutical company aiming to discover novel therapeutics and diagnosis for intractable central nervous system (CNS) diseases caused by low-level somatic mutation.

It is a great honor to be recognized by a jury of such globally respected scientists whom I greatly admire, said Prof. Lee. More importantly, this award validates research into brain somatic mutations as an important area of exploration to help patients suffering from devastating and untreatable neurological disorders.

The 2020 Winners will be honored at the virtual Innovators in Science Award Ceremony and Symposium in October 2020. This event provides an opportunity to engage with leading researchers, clinicians and prominent industry stakeholders from around the world about the latest breakthroughs in the scientific understanding and clinical treatment of genetic, nervous system, metabolic, autoimmune and cardiovascular rare diseases.

At Takeda, patients are our North Star and those with rare diseases are often underserved when it comes to the discovery and development of transformative medicines, said Andrew Plump, M.D., Ph.D., President, Research & Development at Takeda. Insights from the ground-breaking research of scientists like Prof. Krainer and Prof. Lee can lead to pioneering approaches and the development of novel medicines that have the potential to change patients lives. Thats why we are proud to join with the New York Academy of Sciences to broadly share and champion their workand hopefully propel this promising science forward.

Connecting science with the world to help address some of societys most pressing challenges is central to our mission, said Nicholas Dirks, Ph.D., President and CEO, the New York Academy of Sciences. In this third year of the Innovators in Science Award we are privileged to recognize two scientific leaders working to unlock the power of the genome to bring innovations that address the urgent needs of patients worldwide affected by rare diseases.

About the Innovators in Science Award

The Innovators in Science Award grants two prizes of US $200,000 each year: one to an Early-Career Scientist and the other to a well-established Senior Scientist who have distinguished themselves for the creative thinking and impact of their research. The Innovators in Science Award is a limited submission competition in which research universities, academic institutions, government or non-profit institutions, or equivalent from around the globe with a well-established record of scientific excellence are invited to nominate their most promising Early-Career Scientists and their most outstanding Senior Scientists working in one of four selected therapeutic fields of neuroscience, gastroenterology, oncology, and regenerative medicine. Prize Winners are determined by a panel of judges, independently selected by the New York Academy of Sciences, with expertise in these disciplines. The New York Academy of Sciences administers the Award in partnership with Takeda.

For more information please visit the Innovators in Science Award website.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

About the New York Academy of Sciences

The New York Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science, technology, and society worldwide. With more than 20,000 members in 100 countries around the world, the Academy is creating a global community of science for the benefit of humanity. The Academy's core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions and increase the number of scientifically informed individuals in society at large. Please visit us online at http://www.nyas.org.

Continue reading here:
Takeda and the New York Academy of Sciences Announce 2020 Innovators in Science Award Winners - Business Wire

BCLI: KOL Event Gives Overview of the use of NurOwn in Alzheimer’s Disease; Raising Valuation to $25/Share – Zacks Small Cap Research

By David Bautz, PhD

NASDAQ:BCLI

READ THE FULL BCLI RESEARCH REPORT

Business Update

KOL Event for Alzheimers Program

On July 8, 2020, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) conducted a Key Opinion Leader (KOL) webinar to discuss the companys upcoming Phase 2a clinical trial of NurOwn in patients with Alzheimers Disease (AD). The event included presentations by two of the lead investigators for the upcoming trial, Dr. Philip Scheltens, Professor of Cognitive Neurology and Director of the Alzheimer Centre at VU University Medical Center in Amsterdam, Netherlands, and Dr. Bruno Dubois, Professor of Neurology at the Neurological Institute of the Salptrire University Hospital in Paris, France. The presentation can be found here.

The companys Phase 2a trial (BCT-201-EU) is expected to enroll approximately 40 patients with prodromal to mild AD. It will be taking place at medical centers in France and the Netherlands. To be eligible for the trial, patients must have been diagnosed with prodromal to mild dementia at least six months prior to enrollment. In addition, patients must score between 20-30 on the Mini-Mental State Exam (MMSE) and have a Clinical Dementia Rating (CDR) global score of 0.5-1.0. The MMSE is a series of questions that are designed to assess a patients mental skills, with the maximum score being 30 points and a score of 20-24 suggesting mild dementia. The CDR is a scale used to characterize six domains of cognitive and functional performance with a score of 0.5 suggesting very mild dementia and a score of 1.0 suggesting mild dementia.

The primary objective of the trial is to assess the safety and tolerability of three intrathecal injections of NurOwn in AD patients. Following bone marrow aspiration during a 10-week run-in period, patients will be treated three times with NurOwn, with eight weeks between treatments. Follow-up visits will occur 12 and 26 weeks following the final injection of NurOwn for a total trial length of 52 weeks. The following figure gives an overview of the trial design.

Cerebrospinal fluid (CSF) and serum will be collected prior to treatment and again at Weeks 0, 8, and 16 to assess changes in various neurotropic, neurodegenerative, and inflammatory factors (e.g., VEGF, HGF, NfL, NfH, MCP-1, IL-6), markers associated with amyloid deposition (e.g., a40, a42), and markers of tau protein levels (e.g., p-tau, t-tau). Additional clinical outcome measures will be analyzed through administration of the following tests:

Clinical Dementia Rating ScaledSum of Boxes (CDR-SB)

Free and Cued Selective Reminding Test (FCSRT)

Neuropsychological Test Battery (NTB)

Delis-Kaplan Executive Function System (D-KEFS) subtests

Mini Mental State Examination(MMSE)

AmsterdamInstrumentalActivitiesofDailyLivingQuestionnaire-ShortVersion(A-IADL-Q-SV)

Alzheimers Disease

Alzheimers disease (AD) is the most common form of dementia in older adults. The disease is named after Dr. Alois Alzheimer, who identified the first case in a 50-year-old woman named Auguste Deter in 1902. Dr. Alzheimer followed her case until her death in 1906, at which point he first publicly reported on it (Alzheimer, 1907).

After Ms. Deters death, Dr. Alzheimer examined her brain and found many abnormal clumps (now known as amyloid plaques) and tangled bundles of fibers (now known as neurofibrillary tangles). Over the next five years, 11 similar cases were reported in the medical literature, with some of them already using the term Alzheimers disease (Berchtold et al., 1998).

The most common early symptom of AD is a gradually worsening ability to remember new information. This is due to neurons associated with forming new memories dying off first. As neurons in other parts of the brain die, individuals experience different symptoms, which include:

Memory loss that disrupts daily life

Inability to plan or solve problems

Difficulty completing familiar tasks

Confusion with location and time

Difficulty with visual images and spatial relationships

Problems with words in speaking or writing

Withdrawal from social activities

Changes in mood, including apathy and depression

Each person progresses through AD at a different rate, and little is known about how or why there is such a marked variation, thus predicting how it will affect someone is quite difficult. One thing that is common to everyone diagnosed with AD is that his or her cognitive and functional abilities will gradually decline. As the disease progresses symptoms can include confusion, irritability, aggression, mood swings, and long-term memory loss. In the final advanced stage of the disease, people need help with the basic activities of living (e.g., bathing, dressing, eating, and using the restroom), they lose the ability to communicate, fail to recognize loved ones, and eventually become bed bound and reliant on round-the-clock care (Frstl et al., 1999). The inability to move makes them more prone to infections, including pneumonia, which are often a contributing factor to the death of those with AD.

Competing Theories for the Cause of Alzheimers

The root cause of Alzheimers is still unknown; however, it is likely to involve a number of different factors as opposed to being due to one single cause. These factors are likely a combination of genetic, environmental, and lifestyle. There are a number of hypotheses that exist to explain the cause of the disease, with the two dominant hypotheses focused on amyloid and tau.

Amyloid hypothesis: This hypothesis proposes that extracellular beta-amyloid deposits are the fundamental cause of the disease (Hardy et al., 1991). Beta-amyloid is a fragment of the larger protein amyloid precursor protein (APP), mutations of which are known to cause FAD. Several lines of evidence support the amyloid hypothesis: 1) the location of APP is on chromosome 21, while those with Down Syndrome (trisomy 21) almost all show signs of AD by 40 years of age (Lott et al., 2005); 2) APOE4 is a major genetic risk factor for AD, and while apolipoproteins enhance the breakdown of beta-amyloid, some isoforms are less capable of performing this task than others, leading to more beta-amyloid buildup on the brain (Polvikoski et al., 1995); 3) mice that harbor a mutant form of APP develop amyloid plaques and Alzheimers-like pathology (Games et al., 1995). Lastly, amyloid plaques are readily identifiable by microscopy in the brains of AD patients (Tiraboschi et al., 2004). While the brains of many older individuals develop some plaques, the brains of AD patients show severe pathological changes specifically within the temporal neocortex (Bouras et al., 1994).

Tau hypothesis: Tau is a protein located mainly within the axonal compartment of neurons and is an important element in microtubule stabilization and neurite outgrowth. In AD, a proportion of tau protein becomes abnormally phosphorylated, dissociates from axonal microtubules, and accumulates in paired helical filaments inside the neuron (Goedert et al., 1991). When this occurs, the microtubules disintegrate causing the collapse of the neurons transport system (Igbal et al., 2005). Just as with beta-amyloid plaques, tau tangles are readily observable in the brains of those affected by AD.

In addition to amyloid and tau, inflammation has been an underappreciated and often overlooked mediator in patients with AD (Akiyama et al., 2000). A multitude of inflammatory markers are found in AD patients brains and a number of studies have shown a link between chronic inflammation and an increased risk of developing AD (Walker et al., 2017; Tao et al., 2018). Thus, a treatment such as NurOwn that can decrease inflammatory mediators could prove beneficial in AD patients.

On Track to Repot Topline Data from Phase 3 ALS Trial in 4Q20

On July 2, 2020, BrainStorm announced that all doses have been administered in the pivotal Phase 3 trial ofrecen NurOwn in patients with amyotrophic lateral sclerosis (ALS) and that it remains on track to report topline data in the fourth quarter of 2020.

The ongoing randomized, double blind, placebo controlled, multi-dose Phase 3 clinical trial is testing the ability of NurOwn to alter disease progression as measured by the ALSFRS-R (NCT03280056). Cells were extracted once from each patient prior to treatment, with all administrations of NurOwn derived from the same extraction of cells due to a cryopreservation process the company developed for long-term storage of mesenchymal stem cells (MSC). Just as with the companys prior studies, there was a 3-month run-in period prior to the first treatment with two additional NurOwn treatments occurring two and four months following the first treatment. The company is focusing the trial on faster-progressing ALS patients since those patients demonstrated superior outcomes in the Phase 2 trial of NurOwn.

BrainStorm Joins Russell 2000 and Russell 3000; Granted SME Status by EMA

On June 23, 2020, BrainStorm announced that its shares would be included in the Russell 2000 Index and the Russell 3000 Index. The annual reconstitution of the Russell indexes is done to capture the 4,000 largest U.S. stocks by market capitalization.

On June 15, 2020, BrainStorm announced that the company has been granted Small and Medium-Sized Enterprise (SME) status by the European Medicines Agency (EMA). SME status allows the company to participate in a number of financial incentives including a 90-100% reduction in the EMA fee for scientific advice, clinical study protocol design, endpoints and statistical considerations, quality inspections of facilities, and fee waivers for selective EMA pre- and post-authorization regulatory filings, including Orphan Drug and PRIME designations.

Conclusion

Were excited about the potential for NurOwn in AD and we look forward to the initiation of the Phase 2a trial later in 2020. We have recently made a few changes to our model, including the inclusion of NurOwn in AD and lowering of the discount rate from 20% to 15% for all indications. We model for the company to file for approval of NurOwn in AD in 2026 and to be granted approval in 2027. We currently estimate peak sales of over $2 billion for NurOwn in AD in both the U.S. and E.U. Using a 25% probability of approval leads to an NPV of $113 million. Combined with the NPV for NurOwn in ALS ($700 million) and MS ($41 million) along with the companys current cash position and potential cash from warrants leads to a valuation for the company of a bit less than $900 million. Dividing by the companys current fully diluted share count of 35.7 million leads to a valuation of $25 per share.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCHtoreceive our articles and reports emailed directly to you each morning. Please visit ourwebsitefor additional information on Zacks SCR.

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.

Link:
BCLI: KOL Event Gives Overview of the use of NurOwn in Alzheimer's Disease; Raising Valuation to $25/Share - Zacks Small Cap Research

IML conducts the 5th National Convention on Medicine and Law – ETHealthworld.com

Mumbai July 07, 2020 : Institute of Medicine & Law (IML) conducted the 5th National Convention on Medicine & Law on July 05, 2020. This event is an influential and foremost meeting that discusses and deliberates on changes needed in laws relating to healthcare in India.

Session 1 was on Organ Transplant in India Legal Issues and Solutions, and a few prominent problems, issues, and recommendations discussed various issues like - low allocation in the state's budget for health, fear psychosis among doctors, definitions of death in Indian law, coordination between public and private hospitals, need for more hospitals as organ retrieval centres, procedures governing declaration of brain-stem death, etc,

Session 2 was on Legal & Regulatory Framework for Tele-Health The Way Forward and a few prominent problems, issues, and recommendations discussed the need for comprehensive and overarching legislation, apprehensions in minds of doctor and patients, security of data, confidentiality, privacy, commercialization of medicine, acceptance of telemedicine by medical insurance providers & indemnity providers to doctors and hospitals, problem of patients calling at odd hours, not paying fees, data charges of platforms, patients outside India, friendly advice, informal chats, adverse event reporting, bad audio / video, managing data, cyber security, different types of consultations, and so on needs to be clarified.

Dr. T N Ravishankar, ex-President, IMA Tamil Nadu was the convenor of the first session, whereas Dr. Dilip Walke, ex-President, Medico-Legal cell, FOGSI was convenor of the second session. Dr. Parag Rindani, CEO Wokhardt Hospital, Mumbai Central was the moderator of both the sessions.

Dr. Bhagwat Karad, Member of Parliament, Rajya Sabha and himself a paediatric surgeon noted that the convention has involved everybody, viz. doctors, experts in law, patient group, and representation from other countries also.

A doctor has done his job till such time as he has given a reasonable standard of care. As a judge whenever a case would come to me, the scales of justice would always shift in favour of the doctor said Justice Sunil Ambwani, Former Chief Justice of Rajasthan High Court, and also the Chairperson of the e-committee, Supreme Court of India.

The nation today needs a central law on uniform determination of death, even the WHO has recommended, and many countries are following this was one of the key recommendations that was proposed by Mahendrakumar Bajpai, Advocate Supreme Court.

Go here to read the rest:
IML conducts the 5th National Convention on Medicine and Law - ETHealthworld.com

Could induced pluripotent stem cells be the breakthrough …

Embryonic stem cells. The ethical issues associated with stem cell research could be resolved through the use of induced pluripotent stem cells, which are derived from fully committed and differentiated cells of the adult body

The almost miraculous benefits that stem cells may one day deliver have long been speculated on. Capable of becoming different types of cells, they offer huge promise in terms of transplant and regenerative medicine. It is, however, also a medical field that urges caution one that must constantly battle exaggeration. If stem cells do in fact hold the potential to reverse the ageing process, for example, then such breakthroughs remain many years away.

Recently, though, the field has had cause for excitement. In 2006, Japanese researcher Shinya Yamanaka discovered that mature cells could be reprogrammed to become pluripotent, meaning they can give rise to any cell type of the body. In 2012, the discovery of these induced pluripotent stem cells (iPSCs) saw Yamanaka and British biologist John Gurdon awarded the Nobel Prize in Physiology or Medicine. Since then, there has been much talk regarding the potential iPSCs possess, not only for the world of medicine, but for society more generally, too.

A big stepHistorically, one of the major hurdles preventing further research into stem cells has been an ethical one. Until the discovery of iPSCs, embryonic stem cells (ESCs) represented the predominant area of research, with cells being taken from preimplantation human embryos. This process, however, involves the destruction of the embryo and, therefore, prevents the development of human life. Due to differences in opinion over when life is said to begin during embryonic development, stem cell researchers face an ethical quandary.

The promise of significant health benefits and new revenue streams has led some clinics to offer unproven stem cell treatments to individuals

With iPSCs, though, no such dilemmas exist. IPSCs are almost identical to ESCs but are derived from fully committed and differentiated cells of the adult body, such as a skin cell. Like ESCs, iPSCs are pluripotent and, as they are stem cells, can self-renew and differentiate, remaining indefinitely propagated and retaining the ability to give rise to any human cell type over time.

One important distinction to make is that both ESCs and iPSCs do not exist in nature, Vittorio Sebastiano, Assistant Professor (Research) of Obstetrics and Gynaecology (Reproductive and Stem Cell Biology) at Stanford Universitys Institute for Stem Cell Biology and Regenerative Medicine, told The New Economy. They are both beautiful laboratory artefacts. This means that at any stage of development, you cannot find ESCs or iPSCs in the developing embryo, foetus or even in the postnatal or adult body. Both ESCs and iPSCs can only be established and propagated in the test tube.

The reason neither ESCs nor iPSCs can be found in the body is that they harbour the potential to be very dangerous. As Sebastiano explained, these cells could spontaneously differentiate into tumorigenic masses because of their intrinsic ability to give rise to any cell type of the body. Over many years of research, scientists have learned how to isolate parts of the embryo (in the case of ESCs) and apply certain culture conditions that can lock cells in their proliferative and stem conditions. The same is true for iPSCs.

To create iPSCs, scientists take adult cells and exogenously provide a cocktail of embryonic factors, known as Yamanaka factors, for a period of two to three weeks. If the expression of such factors is sustained for long enough, they can reset the programme of the adult cells and establish an embryonic-like programme.

Turning back the clockThere is already a significant body of research dedicated to how stem cells can be used to treat disease. For example, mesenchymal stem cells (usually taken from adult bone marrow) have been deployed to treat bone fractures or as treatments for autoimmune diseases. It is hoped that iPSCs could hold the key for many more treatments.

Global stem cell market:25.5%Expected compound annual growth rate (2018-24)$467bnExpected market value (2024)

IPSCs are currently utilised to model diseases in vitro for drug screening and to develop therapies that one day will be implemented in people, Sebastiano explained. Given their ability to differentiate into any cell type, iPSCs can be used to differentiate into, for example, neurons or cardiac cells, and study specific diseases. In addition, once differentiated they can be used to test drugs on the relevant cell type. Some groups and companies are developing platforms for cell therapy, and I am personally involved in two projects that will soon reach the clinical stage.

Perhaps the most exciting prospects draw on iPSCs regenerative properties. Over time, cells age for a variety of reasons namely, increased oxidative stress, inflammation and exposure to pollutants or sunlight, among others. All these inputs lead to an accumulation of epigenetic mistakes those that relate to gene expression rather than an alteration of the genetic code itself in the cells, which, over time, results in the aberrant expression of genes, dysfunctionality at different levels, reduced mitochondrial activity, senescence and more besides. Although the epigenetic changes that occur with time may not be the primary cause of ageing, the epigenetic landscape ultimately affects and controls cell functionality.

What we have shown is that, if instead of being expressed for two weeks we express the reprogramming factors for a very short time, then we see that the cells rejuvenate without changing their identity, Sebastiano said. In other words, if you take a skin cell and express the reprogramming genes for two to four days, what you get is a younger skin cell.

By reprogramming a cell into an iPSC, you end up with an embryonic-like cell the reprogramming erases any epigenetic errors. If expressed long enough, it erases the epigenetic information of cell identity, leaving embryonic-like cells that are also young.

Slow and steadyAs with any scientific advancement, financial matters are key. According to Market Research Engine, the global stem cell market is expected to grow at a compound annual growth rate of 25.5 percent between 2018 and 2024, eventually reaching a market value of $467bn. The emergence of iPSCs has played a significant role in shaping these predictions, with major bioscience players, such as Australias Mesoblast and the US Celgene, working on treatments involving this particular type of stem cell.

The business potential around stem cell research is huge, Sebastiano told The New Economy. [Particularly] when it comes to developing cell banks for which we have detailed genetic information and, for example, studying how different drugs are toxic or not on certain genetic backgrounds, or when specific susceptibility mutations are present.

Unfortunately, even as the business cases for iPSC treatments increase, a certain degree of caution must be maintained. The promise of significant health benefits and new revenue streams has led some clinics to offer unproven stem cell treatments to individuals. There have been numerous reports of complications emerging, including the formation of a tumour following experimental stem cell treatment in one particular patient, as recorded in the Canadian Medical Association Journal last year. Such failures risk setting the field back years.

The challenge for researchers now will be one of balance. The potential of iPSCs is huge both in terms of medical progress and business development but can easily be undermined by misuse. Medical advancements, particularly ones as profound as those associated with iPSCs, simply cannot be rushed.

Read more here: Could induced pluripotent stem cells be the breakthrough genetics has been waiting for? - The New Economy

More:
Could induced pluripotent stem cells be the breakthrough ...